Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters
about
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistanceClostridium difficile infection: molecular pathogenesis and novel therapeuticsThe potential for emerging therapeutic options for Clostridium difficile infectionA Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionEffects of huoxiangzhengqi liquid on enteric mucosal immune responses in mice with Bacillus dysenteriae and Salmonella typhimurium induced diarrheaThe roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Future novel therapeutic agents for Clostridium difficile infection.The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.Clostridium difficile drug pipeline: challenges in discovery and development of new agentsIn vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004Models for the study of Clostridium difficile infection.In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.Development potential of rifalazil and other benzoxazinorifamycins.Past, present, and future therapies for Clostridium difficile-associated disease.The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challengeThe membrane as a target for controlling hypervirulent Clostridium difficile infections.New advances in the treatment of Clostridium difficile infection (CDI)Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.Clinical update for the diagnosis and treatment of Clostridium difficile infection.The enterotoxicity of Clostridium difficile toxins.Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infectionInhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.Efficacy of LFF571 in a hamster model of Clostridium difficile infection.MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015.Clostridial typhlitis associated with topical antibiotic therapy in a Syrian hamster.Treatment of Clostridium difficile infection.Establishment of an Endogenous Clostridium difficile Rat Infection Model and Evaluation of the Effects of Clostridium butyricum MIYAIRI 588 Probiotic Strain.Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection
P2860
Q24632641-03661EB4-F1BD-48D3-BB10-4F18BFEFDE77Q26864237-33B5790B-5933-4E53-98BB-12A6334B22EAQ28082059-97BF6274-1CED-4DCE-AF13-AEE1C03F72B5Q30240264-6B2718B4-B1B4-4FC9-A210-6D3CAC17875FQ33866510-ABDFDAB8-9C6D-4EE7-A1A2-DC6BC44A8E00Q34623572-F9DA78E6-C111-477E-97AA-FE8DC968B5A0Q35044119-7F034803-E525-4D3B-AC22-9BEF44B490EAQ35175136-B80B73D6-1BA5-463E-9E77-E747DA4A937AQ35270823-E783F492-9629-440E-BD4B-DB91F1C0C712Q35846436-45F41A6B-2F37-454B-91B6-24641A2B3942Q35912682-3C59E924-C10B-4941-A0FA-B232B360E697Q36019356-ED71F226-B961-4C8F-B058-22B9D9BE69A2Q36364070-D99DD577-DEC6-457E-B08F-2B1FF8FAB251Q36367042-83609800-CCB5-40A3-98C8-8677CB771B3CQ36482832-A4916E90-5BF0-4065-9CBF-780960FE3F3DQ36491823-19FF2718-A41E-4059-AD78-FFF81F63AFB6Q36674768-F0BBA322-CF52-4735-93CA-0CAA8C5E0BDAQ36889259-056A1609-A875-4C5A-A7B9-45748190A384Q36963920-F8E91320-CE3C-439E-BEB1-9F1DD69B1D37Q37052819-370D710F-8081-4551-A627-F2D1AC9C965EQ37145568-D6F36431-6FAF-4806-AFB0-81C4B7CD631FQ37633859-63D7565B-C12B-4180-9268-9666463691B5Q37954308-BFC92F75-B73A-45B7-BE07-97576D0C0DC2Q39078400-119A290B-15F5-4372-ADE7-9B5AD99884CAQ39878458-B1657C4C-BA08-46ED-94D6-85A248C2EEE5Q42280743-8DD1502E-65EE-40BA-A2AA-E0909ADBD107Q42281252-31F7485A-326C-4049-80B7-530E6D11B972Q51084446-3FD8B39C-8B21-4ED6-86AC-BF7F74B98ED7Q51782758-9CC25671-AA46-4A3B-AD47-7760FBD89C9DQ51894323-11BC4BCC-CEA0-4F07-8BC8-BF01A4A8F120Q55387501-B242484B-12BB-40B8-B04A-3801E7F561EEQ57107809-F3506A81-5629-4EBA-B4D5-27DC9C02E8C6
P2860
Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@ast
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@en
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@nl
type
label
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@ast
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@en
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@nl
prefLabel
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@ast
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@en
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@nl
P2093
P2860
P1476
Rifalazil treats and prevents ...... ssociated diarrhea in hamsters
@en
P2093
Arthur Michaelis
Barry Eisenstein
Charalabos Pothoulakis
Ciáran P Kelly
David Rothstein
Efi Kokkotou
Sophia Paraschos
P2860
P304
P356
10.1128/AAC.48.10.3975-3979.2004
P407
P577
2004-10-01T00:00:00Z